San Francisco Department of Veterans Affairs Medical Center
San Francisco, California, 94121, United States
NCT Number: NCT00312962
This study will determine the effectiveness of reward-intensive, computer-based targeted cognitive training in improving neurocognitive deficits in people with schizophrenia.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1 / Phase 2
San Francisco, California, 94121, United States
Schizophrenia is a chronic brain disorder that causes severe disability. It is characterized by psychotic symptoms, including hallucinations and delusions. Neurocognitive deficits, such as impaired neurocognitive processing efficiency, also affect people with schizophrenia. This deficiency in the speed and accuracy with which the brain perceives and responds to targets causes scrambled messages to be transmitted in the brain, thereby affecting executive control and memory. Medications are available that effectively treat the psychotic symptoms. The neurocognitive deficits, however, do not subside with medication treatment, and are responsible for the failure to improve the e their psychosocial functioning of people with schizophrenia, even after their psychotic symptoms have gone into remission. The targeted cognitive training (TCT) exercises in this study are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets. This study will determine the effectiveness of reward-intensive, computer-based TCT in improving neurocognitive deficits in people with schizophrenia.
Participants in this double-blind study will be paired according to IQ and baseline symptom severity. One member of each pair will be randomly assigned to training exercises that use TCT. The other will be assigned to a control intervention, which will involve commercially available computer games. All participants will complete exercises with their assigned intervention for 1 hour per day, 5 days per week, until 90 hours of training has been accumulated. Neuroimaging will be performed on a subgroup of participants to examine changes in brain activation patterns in response to the cognitive training. Upon study completion and at the 6-month follow up visit, participants will be assessed for improvement in the following areas: cognitive performance; symptom profile; quality of life; and social cue recognition.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
Time frame: Measured at Weeks 8, 14, and 8 and Month 6 follow-up
Time frame: Measured at Weeks 8, 14, and 8 and Month 6 follow-up
Time frame: Measured at Weeks 8, 14, and 8 and Month 6 follow-up
University of California, San Francisco
Other
Neuroscience-Guided Remediation of Cognitive Deficits in Schizophrenia
Acronym: CRIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial DetailsNCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial DetailsNCT00001247
Mental Disorders, Psychotic Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT00001258
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial Details